

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Confirmation No. 4646

Hiide YOSHINO et al.

Attorney Docket No. 2006 1312A

Serial No. 10/588,778

Group Art Unit 1612

Filed August 8, 2006

Examiner Marcos L. Sznaidman

A NOVEL THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS

(ALS) OR DISEASES CAUSED BY ALS

Mail Stop: Amendment

RESPONSE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

MAISSIONER IS AUTHORIZED ANY DEFICIENCY IN THE **SIS PAPER TO DEPOSIT**

This is responsive to the Official Action dated March 31, 2009.

The Official Action constitutes a requirement for an election of species.

Applicants elect 3-methyl-1-phenyl-2-pyrazoline-5-on (edaravone) recited in claims 2 and 18, namely a compound of the formula (I) wherein R1 is methyl, R2 is a hydrogen atom and R3 is a phenyl.

The claims readable on the elected species are claims 1-32.

Favorable action on the merits is solicited.

Respectfully submitted, Hiide YOSHINO et al.

Warren M. Cheek Registration No. 33,367

Wachele

Attorney for Applicants

WMC/dlk Washington, D.C. 20005-1503 Telephone (202) 721-8200 Facsimile (202) 721-8250 April 29, 2009